Cargando…
C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation
Two consecutive multi-center phase II trials were designed to prove the hypothesis, whether therapeutic modeling of tumor-associated inflammatory processes could result in improved tumor response. Therapy in both trials consisted of low-dose capecitabine 1g/m2 twice daily p.o. for 14 days, every 3 w...
Autores principales: | Reichle, Albrecht, Grassinger, Jochen, Bross, Klaus, Wilke, Jochen, Suedhoff, Thomas, Walter, Bernhard, Wieland, Wolf-Ferdinand, Berand, Anna, Andreesen, Reinhard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716790/ https://www.ncbi.nlm.nih.gov/pubmed/19690640 |
Ejemplares similares
-
Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan
por: Vogelhuber, M., et al.
Publicado: (2014) -
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma
por: Meyer, Stefanie, et al.
Publicado: (2010) -
Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial
por: Reinhold, Stephan W, et al.
Publicado: (2011) -
Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020) -
The importance of clear language
por: Ranstam, Jonas
Publicado: (2013)